Analysts Set REGENXBIO Inc. (NASDAQ:RGNX) PT at $34.82

Shares of REGENXBIO Inc. (NASDAQ:RGNX) have earned an average rating of “Moderate Buy” from the twelve brokerages that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $34.82.

A number of analysts recently issued reports on RGNX shares. Royal Bank of Canada restated an “outperform” rating and issued a $30.00 price target on shares of REGENXBIO in a research report on Tuesday, January 21st. HC Wainwright restated a “buy” rating and issued a $36.00 target price on shares of REGENXBIO in a report on Wednesday, January 15th. Morgan Stanley reiterated an “overweight” rating and set a $22.00 price target on shares of REGENXBIO in a report on Friday, November 15th. Chardan Capital restated a “buy” rating and set a $52.00 target price on shares of REGENXBIO in a research report on Wednesday, November 20th. Finally, Raymond James reiterated an “outperform” rating and issued a $18.00 price target on shares of REGENXBIO in a report on Thursday, October 10th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in RGNX. Redmile Group LLC boosted its position in REGENXBIO by 7.1% during the third quarter. Redmile Group LLC now owns 4,892,902 shares of the biotechnology company’s stock valued at $51,327,000 after purchasing an additional 323,100 shares in the last quarter. Geode Capital Management LLC grew its position in shares of REGENXBIO by 4.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,088,651 shares of the biotechnology company’s stock worth $11,422,000 after buying an additional 44,037 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in shares of REGENXBIO by 53.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company’s stock worth $6,621,000 after acquiring an additional 296,700 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in REGENXBIO by 9.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 417,739 shares of the biotechnology company’s stock valued at $4,382,000 after acquiring an additional 37,055 shares during the last quarter. Finally, Millennium Management LLC lifted its position in REGENXBIO by 84.8% during the second quarter. Millennium Management LLC now owns 306,487 shares of the biotechnology company’s stock valued at $3,586,000 after acquiring an additional 140,666 shares during the last quarter. 88.08% of the stock is currently owned by hedge funds and other institutional investors.

REGENXBIO Price Performance

Shares of NASDAQ RGNX opened at $8.43 on Friday. REGENXBIO has a 1-year low of $6.56 and a 1-year high of $28.80. The business’s 50 day moving average is $8.18 and its two-hundred day moving average is $10.13. The stock has a market capitalization of $417.62 million, a P/E ratio of -1.68 and a beta of 1.29.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.